Compare FOXF & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | VERA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.2M | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | FOXF | VERA |
|---|---|---|
| Price | $17.66 | $54.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $33.00 | ★ $76.60 |
| AVG Volume (30 Days) | 1.0M | ★ 1.9M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,459,086,000.00 | N/A |
| Revenue This Year | $6.82 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.22 | N/A |
| 52 Week Low | $13.08 | $18.53 |
| 52 Week High | $31.18 | $55.00 |
| Indicator | FOXF | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 81.32 |
| Support Level | $16.93 | $47.22 |
| Resistance Level | $17.84 | $51.19 |
| Average True Range (ATR) | 0.64 | 3.06 |
| MACD | 0.34 | 0.62 |
| Stochastic Oscillator | 86.27 | 94.38 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.